Company / Revenue
Ernexa Therapeutics Inc. Revenue History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$582.0K
FY2025
5-year range
$0 / $23.3M
FY2021-FY2025
Trend
+755.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue changed +756% YoY in FY2025, a notable deviation from the 8-year average annual change of +80%.
Based on SEC 10-K filings.
$582,000 in FY2025 with a 10-year CAGR of -31.6%.
Improved from $0 to $582,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -50.6%
- 10-Year CAGR
- -31.6%
Key checks
Key Insights
- 5-year CAGR of -50.6%, indicating a declining trend.
- In FY2025, revenue increased 755.9% year-over-year.
- Peak revenue was recorded in FY2015.
- Lowest revenue in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $582.0K | +755.9% |
| FY2024 | $68.0K | - |
| FY2023 | $0 | -100.0% |
| FY2020 | $19.8M | -15.1% |
| FY2019 | $23.3M | +9.7% |
| FY2018 | $21.3M | -4.7% |
| FY2017 | $22.3M | -9.0% |
| FY2016 | $24.5M | -5.9% |
| FY2015 | $26.0M | +9.7% |
| FY2014 | $23.7M | -1.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026